Educational reference only. Informational material drawn from peer-reviewed literature. Not medical advice and not a recommendation to use, dose, or modify any therapy. Decisions about hormone therapy should be made with a qualified healthcare provider.
Overview
Overview
Nandrolone is a synthetic anabolic-androgenic steroid (AAS) and one of the most clinically studied compounds in this class. It is best known by the trade name Deca-Durabolin (nandrolone decanoate, the long-acting injectable form) and Durabolin (nandrolone phenylpropionate, a shorter-acting form). Nandrolone has the distinction of being the only major 19-nor anabolic steroid with current FDA approval for human use, specifically for anemia associated with chronic kidney failure.
Nandrolone was first synthesized in 1957 and approved by the FDA on October 30, 1959 as Durabolin (nandrolone phenylpropionate) by Organon for the treatment of breast cancer. The decanoate ester followed, marketed as Deca-Durabolin, with broader clinical applications. The compound has been extensively studied in conditions including HIV-associated wasting, osteoporosis, chronic kidney disease, COPD, and cachexia.
Once cleaved from the ester, the nandrolone molecule itself has a short circulating half-life of several hours. The ester is the rate-limiting step for the long duration of action.
Forms
Available forms & half-lives
| Form | Approximate half-life |
|---|---|
| Phenylpropionate (Durabolin) | ~2.7 days |
| Decanoate (Deca-Durabolin) | ~7–12 days |
What it does
Main effects
- Strong anabolic activity with favorable AR-mediated tissue profile: clinically demonstrated lean-mass gains in HIV wasting trials PMID: 10199766
- Bone-protective effects: reduced fracture risk demonstrated in postmenopausal women in a 2024 meta-analysis PMC: 12748007; basis of one of the compound's continuing therapeutic uses
- Stimulation of erythropoiesis: the basis of the current FDA-approved indication (anemia of chronic kidney failure)
- Reduced androgenic effects in scalp/skin/prostate vs. testosterone, because 5α-reduction produces the weaker metabolite dihydronandrolone (not the more potent DHT)
- Modest aromatization (~20% of testosterone's rate): some estradiol elevation but substantially less per milligram than testosterone
- Joint comfort improvement widely reported by users and supported by limited clinical data. Mechanism may involve collagen turnover and anti-inflammatory effects
What to watch for
Common side effects
- Prolactin-mediated sexual dysfunction: one of the most consistently reported features; via progesterone receptor activity raising prolactin; reduced libido, erectile dysfunction, sometimes galactorrhea
- Profound HPG axis suppression with extended recovery: long ester half-life means active hormone continues to suppress the axis for weeks after the last injection; recovery often slow and sometimes incomplete
- Modest estradiol elevation: at ~20% the rate of testosterone, can still contribute to gynecomastia; combined with progesterone-receptor effects on breast tissue (independent of estrogen) can drive gyno even with E2 controlled
- HDL reduction (20–30% at therapeutic doses) and LDL elevation: documented across clinical trials
- Erythrocytosis: AAS-class effect; less pronounced than testosterone or trenbolone at equivalent doses
- Acne, oily skin, scalp hair loss: generally milder than testosterone due to weaker DHN metabolite, but still present
- Critical 5α-reductase inhibitor interaction: finasteride/dutasteride may WORSEN nandrolone's androgenic effects (opposite of their effect with testosterone), because they prevent conversion to the weaker dihydronandrolone
- Exceptionally long detection window: decanoate metabolites detectable in urine for up to 18 months; among the most easily caught compounds in WADA testing
- Virilization risk in women: voice deepening and clitoral enlargement are often partially or fully irreversible; lower per-milligram risk than more androgenic compounds but not absent
Key facts
Key facts worth knowing
- Nandrolone is structurally testosterone with the C19 methyl group removed, making it the prototype "19-nor" steroid. Trenbolone and trestolone are both further modifications of this 19-nor structure.
- A meta-analysis published in 2024 of randomized trials demonstrated reduced fracture risk and improvements in bone mineral density with nandrolone decanoate use in postmenopausal osteoporosis. PMC: 12748007
- Unlike testosterone (which is converted to the more potent DHT by 5α-reductase), nandrolone is converted to the weaker metabolite dihydronandrolone. This is the basis for nandrolone's relatively favorable profile in androgen-sensitive tissues like the prostate and scalp compared to testosterone.
- Like trenbolone and trestolone, nandrolone has progesterone receptor activity and can elevate prolactin. This produces sexual dysfunction associated with extended nandrolone use, a significant harm-reduction consideration that many users underestimate.
- Nandrolone has an exceptionally long detection window for sport testing. The decanoate ester can be detected in urine for up to 18 months after the last dose, making it one of the most easily caught compounds in WADA testing.
- The Sattler 1999 randomized trial is the foundational human RCT demonstrating nandrolone's efficacy in HIV-related muscle wasting when combined with progressive resistance training. PMID: 10199766
Legal status
Legal status
Schedule III controlled substance in the United States (DEA). FDA-approved for anemia of chronic kidney failure (generic nandrolone decanoate). WADA-prohibited at all times in competitive sport.